A board's scarcest asset is its attention. Avancer's heat map rates twelve board duties by AI impact for health systems, medical device and diagnostics companies, pharmaceutical and biotechnology companies, and health plans, adjusts two duties for public companies, and shows how the ratings set the agenda.

For organizations that use AI across borders, the hardest part of AI governance is not the technology. It is the divergence of the rules, and the board should set a regulatory risk appetite for it.